STEAP4

Across TCGA pan-cancer cohorts, STEAP4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STEAP4 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher STEAP4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STEAP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and LUAD are the cancer types where STEAP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.047	0.783	<.001	21	view →
UCEC	DFS	Median	II,III,IV	0.928	0.435	.020	16	view →
LUAD	OS	Median	All	0.236	0.812	.001	15	view →
UCS	OS	Median	II,III,IV	0.007	0.616	<.001	12	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STEAP4–LIHC (OS)

Open the LIHC breakdown →